Auspherix Raises £6Million to Progress its Novel Antibiotics and Establishes UK Operations
In the race to develop new antibiotics with completely new modes of action that might address the growing threat posed by antimicrobial resistance, Auspherix Limited (UK), an early stage anti-infectives company originated in Sydney Australia, has raised £6 million in a Series A venture financing, and is establishing operations on the Stevenage Bioscience Catalyst site just outside of London, UK. New investor Imperial Innovations plc led the round alongside Australian founding investor the Medical Research Commercialisation Fund (MRCF).
The investment will be used to fund the Company’s drug discovery programme, expand the experienced management team and recruit a world-class microbiology team. Auspherix aims to progress its novel class of antibacterials, which have a unique profile and novel mechanism of action, through lead optimization to final candidate selection within the next two years. Auspherix’s current lead compounds show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial infections.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

HM-Software - Adelheidsdorf, Germany

Lumiphore, Inc. - Richmond, USA

Lactate for Brain Energy
List_of_bolete_species
CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA
Casting a wide net to fight coronaviruses
Sexual transmission of Ebola likely to impact course of outbreaks
How a protein in your brain could protect against Alzheimer's disease - New research sets the stage for new therapeutic strategies for Alzheimer's disease
New model finds HIV acute phase infectivity may be lower than previously estimated

KNAUER is expanding its business activities into the field of lipid nanoparticle production equipment - In connection with the development of mRNA-based vaccines against Corona, LNPs have shown to be a suitable delivery form
